Exploring the Potential of Enhanced Prognostic Performance of NCCN‐IPI in Diffuse Large B‐Cell Lymphoma by Integrating Tumor Microenvironment Markers: Stromal FOXC1 and Tumor pERK1/2 Expression. The gene discussed is FOXC1; the disease is neoplasm.